Drugs / INQOVI
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | INQOVI | — | 2020-07-07 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06357858 | Jun 2024 → Feb 2025 | head and neck squamous cell carcinoma, metastatic squamous cell carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05201066 | Feb 2023 → Feb 2028 expected | chronic myelomonocytic leukemia, myelodysplastic syndrome | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05918055 Background | Nov 2023 → Mar 2025 | myelodysplastic syndrome | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT04878432 Background | Mar 2022 → Oct 2023 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INQOVI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06357858 ↗ |
| Known as | decitabine-cedazuridine | “Inqovi (decitabine-cedazuridine) is an oral formulation of decitabine plus cytidine deaminase inhibitor that was recently Food and Drug Administration (FDA)-approved for MDS,...” NCT05918055 ↗ |
| Route | Oral | “Tablet for oral administration” NCT04878432 ↗ |